Bortezomib Aqueous Formulation Stability via Polyhydroxy Excipients
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Bortezomib, a crucial antineoplastic agent, is unstable in liquid form, particularly in aqueous solutions, leading to rapid degradation and requiring reconstitution from solid forms, which is inconvenient and limits its stability to only 8 hours after preparation.
Innovation Solution
Formulating bortezomib with specific combinations of antioxidants and polyhydroxy excipients, such as mannitol and water-soluble cyclodextrins, creates stable aqueous compositions that can be used directly without reconstitution, maintaining stability for extended periods without the need for lyophilization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If bortezomib is formulated in aqueous solution for direct administration, then ease of operation is improved, but stability deteriorates due to rapid degradation
Solution Approach 1:
The patent introduces polyhydroxy compounds (such as mannitol, sorbitol, or glycerol) as intermediary substances that mediate between the bortezomib drug molecule and the aqueous environment. These polyhydroxy compounds form protective complexes with bortezomib, reducing its exposure to degrading factors in aqueous solution while maintaining solubility and stability for extended periods.
2Stability of the object's composition
If bortezomib is provided in solid lyophilized form, then stability is improved, but device complexity increases due to reconstitution requirements
Solution Approach 1:
The patent extracts and eliminates the lyophilization step from the formulation process by developing stable aqueous formulations that do not require removal of water. This takes out the complex freezing and drying process entirely, allowing the drug to be supplied in a simple liquid form that remains stable without requiring solidification and subsequent reconstitution.
3Productivity
If bortezomib is formulated as ready-to-use aqueous composition, then productivity is improved by eliminating reconstitution steps, but stability deteriorates without lyophilization
Solution Approach 1:
The patent changes critical formulation parameters including the addition of polyhydroxy compounds at specific concentrations, pH adjustment to optimal ranges, and selection of appropriate buffers and excipients. These parameter changes transform the formulation from an unstable aqueous solution to a stable ready-to-use composition that maintains efficacy without requiring lyophilization, thereby enabling direct administration and improving productivity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The stable aqueous compositions of bortezomib exhibit prolonged physical and chemical stability, allowing for extended storage and reduced drug waste, simplifying administration and potentially lowering production costs by eliminating the need for reconstitution steps.
Implementation Method 1
certain combinations of excipients, such as antioxidant and different polyhydroxy excipients, effectively slowed down the degradation of bortezomib in aqueous solutions
Implementation Method 2
certain combinations of excipients, such as antioxidant and different polyhydroxy excipients, effectively slowed down the degradation of bortezomib in aqueous solutions
Data Source
AI summary
Provided herein are novel ready-to-use bortezomib formulations, methods of preparing, and methods of using the same.